Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.850 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
News headline image
The Slide in Ocugen Could Be a Slide to a Homerun ↗
Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin. 
Via InvestorPlace
News headline image
Why This Meme Stock Isn't Worth the Trouble ↗
This biotech is targeting a lucrative market, but it may be too late for the company. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Have More Than Tripled so far This Year ↗
But can they keep up the momentum? 
Via The Motley Fool
News headline image
2 More Stocks Set to 2x… 5x… 10x in 2022 ↗
Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
Via InvestorPlace
Topics Economy
News headline image
3 Things About Ocugen That Smart Investors Know ↗
Revenue may not be right around the corner. 
Via The Motley Fool
News headline image
Ocugen Proves Groupthink Is a Double-Edged Sword ↗
While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition. 
Via InvestorPlace
News headline image
Ocugen Needs More Than Covaxin to Boost Its Falling Shares ↗
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices. 
Via InvestorPlace
News headline image
As OCGN Stock Trudges Along Without Real Hope Must Wane ↗
Ocugen is nothing but false hope despite positive news 
Via InvestorPlace
News headline image
Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy ↗
The company needs clear regulatory wins in the U.S. and Canada. 
Via The Motley Fool
News headline image
Is Ocugen About to Beat Moderna in This One Market? ↗
Ocugen aims to be among the first to carve out market share. 
Via The Motley Fool
News headline image
WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals ↗
Ocugen has been trying to commercialize a Covid-19 vaccine. However, it's facing many obstacles. Meanwhile, insiders are dumping OCGN stock. 
Via InvestorPlace
News headline image
7 Stocks To Sell Before They Head to The Market Graveyard ↗
So, which ones are stocks to sell ASAP? With these seven stocks, all former favorites on both Main Street and Wall Street, consider it high time to take the money and run. 
Via InvestorPlace
News headline image
Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids? ↗
Yes -- but the odds don't look great. 
Via The Motley Fool
News headline image
Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript ↗
OCGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today ↗
OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids. 
Via InvestorPlace
News headline image
7 Meme Stocks Ready to Regain Their Lost Momentum ↗
Aggressive investors looking to profit off of the recent impressive volatility in certain companies may want to consider these meme stocks. 
Via InvestorPlace
News headline image
2 Moonshots That Insiders Are Buying… and 3 They’re Not ↗
The first several days of November saw insiders spend nearly $750 million buying up shares of their companies, which is worth your attention. 
Via InvestorPlace
News headline image
Sell-the-News Moment Is Your Chance to Reload on Ocugen ↗
Even as OCGN stock moves backward, Ocugen's moving forward with a crucial approval 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
Where Will Ocugen Be in 3 Years? ↗
Most likely in the doldrums, but it could be temporary. 
Via The Motley Fool
News headline image
Ocugen Stock Looks Poised to Take a Tumble Right Here ↗
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock. 
Via InvestorPlace
News headline image
Is Ocugen a Buy? ↗
It'll take more than regulatory approvals of its vaccine for it to become a good investment. 
Via The Motley Fool
News headline image
Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids ↗
Ocugen Inc (NASDAQ: OCGN) said that it sent a request to the FDA for an emergency authorization for its COVID-19 vaccine candidate BBV152, known as Covaxin outside... 
Via Benzinga
News headline image
With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News’ ↗
WHO approval for Covaxin doesn't change the game much for OCGN stock, steer clear as it slides back to lower prices. 
Via InvestorPlace
News headline image
Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week ↗
Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
News headline image
This Surprising FDA Announcement Could Be Huge for Ocugen ↗
The agency will allow vaccine boosters to be mixed and matched. 
Via The Motley Fool
News headline image
Is Ocugen's Surge Much Ado About Nothing? ↗
The short answer: Yes. 
Via The Motley Fool
News headline image
81 Biggest Movers From Yesterday ↗
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
News headline image
Avoid Ocugen — The Vaccine Is Too Little, Too Late ↗
With high percentage of vaccination in U.S. and Canada, Ocugen has a limited addressable market. Limited cash flow visibility from vaccine. With the company still waiting for official FDA approval for... 
Via InvestorPlace
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.